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Abstract
Background: The rates of chemotherapy-induced amenorrhea (CIA) associated with docetaxel-based regimens 
reported by previous studies are discordant. For navelbine-based chemotherapies, rates of CIA have seldom been 
reported.
Methods: Of 170 premenopausal patients recruited between January 2003 and September 2008, 78 were treated with 
fluorouracil plus epirubicin and cyclophosphamide (FEC), 66 were treated with docetaxel plus epirubicin (TE), and 26 
were treated with navelbine plus epirubicin (NE). Patient follow-up was carried up every 3-4 months during the first 
year, then every 9-12 months during subsequent years.
Results: In univariate analysis, the rates of CIA were 44.87% for the FEC regimen, 30.30% for the TE regimen and 23.08% 
for the NE regimen (P = 0.068). Significant differences in the rates of CIA were not found between the FEC and TE 
treatment groups (P > 0.05), but were found between the FEC and NE treatment groups (P < 0.05). Furthermore, no 
significant differences were found between the TE and NE regimens (P > 0.05). Tamoxifen use was a significant 
predictor for CIA (P = 0.001), and age was also a significant predictor (P < 0.001). In multivariate analysis, age (P < 0.001), 
the type of chemotherapy regimens (P = 0.009) and tamoxifen use (P = 0.003) were all significant predictors.
Conclusions: Age and administration of tamoxifen were found to be significant predictive factors of CIA, whereas 
docetaxel and navelbine based regimens were not associated with higher rates of CIA than epirubicin-based regimen.
Background
For approximately 25% of women with breast cancer in
the United States, their diagnosis was made prior to the
onset of menopause [1-3]. Adjuvant chemotherapy has
been shown to prolong disease-free survival and overall
survival in younger breast cancer patients [4,5]. However,
a d j u v a n t  c h e m o t h e r a p y  c a n  a l s o  i n d u c e  m a n y  a d v e r s e
effects. These adverse effects include gastrointestinal
reactions, myelosuppression, and suppression of ovarian
function [3,6]. Therefore, for younger women who are
concerned about preserving their fertility, the possibili-
ties of premature menopause and infertility should be
considered in decisions regarding adjuvant chemother-
apy [7].
The main factors contributing to chemotherapy-
induced amenorrhea (CIA) are patient age, and dosage
and schedule of chemotherapy [8]. A favorable effect of
CIA has been observed for disease outcome in premeno-
pausal women [9], and a previous study showed pregnan-
cies following the diagnosis of breast cancer did not
adversely affect the prognosis of early-stage breast cancer
[10]. Another study reported the risk of CIA associated
with adjuvant chemotherapies involving alkylating agents
or anthracyclines to range from 53-89% [11]. Although
docetaxel is widely used in adjuvant chemotherapies pre-
scribed, studies show discordant results in the rates of
CIA associated with docetaxel-based regimens. For
navelbine-based chemotherapies, rates of CIA have sel-
dom been reported.
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In the present study, we evaluated the impact of doc-
etaxel and navelbine in anthracycline-based chemother-
apy regimens on the incidence of CIA for premenopausal
patients diagnosed with breast cancer. The impact of
endocrine therapy (i.e. tamoxifen) following chemother-
apy on the incidence of CIA was also assessed.
Methods
Patients
Between January 2003 and September 2008, 201 pre-
menopausal patients diagnosed with early breast cancer
were recruited at the First Affiliated Hospital of Nanjing
Medical University and Nanjing Maternity and Child
Health Care Hospital of Nanjing Medical University,
Nanjing, Jiangsu, China. The following criteria were the
basis for exclusion of patient data from this retrospective
study: (1) treatment with luteinizing hormone releasing
hormone (LHRH) agonists; (2) bilateral oophorectomy;
(3) recurrent disease within 12 months; (4) stage IV
breast cancer and (5) receiving chemotherapy previously.
Since 13 of the 201 patients received bilateral oophorec-
tomy, 7 had been treated with LHRH, 7 were lost during
follow-up, and 4 had recurrent disease within 12 months,
patient data from only 170 patients were included in this
descriptive study and analyzed.
Information about CIA and will of pregnancy were col-
lected by telephone. All patients provided oral consent
for their clinical data to be reviewed by us. This study has
been performed with the approval of the ethics commit-
tee of the First Affiliated Hospital of Nanjing Medical
University and Nanjing Maternity and Child Health Care
Hospital of Nanjing Medical University, and this study
was in compliance with the Helsinki Declaration. CIA
was defined as the cessation of menses for 12 consecutive
months after the end of chemotherapy for evaluating the
destruction of the ovarian reserve [12,13], and meno-
pause was defined according to National Comprehensive
Cancer Network (NCCN) guidelines. Additional clinical
information collected for this non-randomized study
included age, tumor stage and size, nodal stage, number
of nodes involved and removed, hormone receptor status,
status of other biological variables (i.e. HER2, p53), surgi-
cal treatment (modified radical mastectomy, breast-con-
serving surgery), radiotherapy administered, and
adjuvant chemotherapy or endocrine therapy received.
Rates of CIA were analyzed according to age, chemother-
apy regimen, and tamoxifen use.
Treatment
Adjuvant chemotherapy regimens were determined
based on guidelines in our country and included: (1) for
the FEC regimen, 5-fluorouracil (500 mg/m2), epirubicin
(75 mg/m2), cyclophosphamide (500 mg/m2) on day 1
every 3 weeks for six cycles; (2) for the TE regimen, doc-
etaxel (75 mg/m2), epirubicin (60 mg/m2) on day 1 every
3 weeks for six cycles; (3) for the NE regimen, navelbine
(25 mg/m2) on days 1 and 8, epirubicin (60 mg/m2) on
day 1 every 3 weeks for six cycles. To reach 100% dose, all
the patients treated with TE regimen were granulocyte
colony stimulating factor (G-CSF) supported, and the
patients treated with the other two regimens were also G-
CSF supported in the case of low white blood cell count
(WBC, <3.0 × 109/L on day 10 after chemotherapy). Fol-
lowing adjuvant chemotherapy, tamoxifen was addition-
ally prescribed if patients were positive for estrogen
receptor (ER) and/or progesterone receptor (PR). A sub-
set of patients switched to the aromatase inhibitor after at
least 2-year tamoxifen use, and some patients received
radiotherapy according to NCCN guidelines. Patient fol-
low-up was every 3-4 months for the first year, then every
9-12 months during subsequent years. The median fol-
low-up time from initiation of chemotherapy was 38.5
months (range, 17 - 83 months).
Statistical analysis
Median, percentiles, and range were analyzed for each
continuous variable. The candidate explanatory variables
in the univariate analyses of CIA onset were: age at diag-
nosis, chemotherapy regimen, and use of tamoxifen.
Fisher's exact test was used for univariate analyses and
logistic regression was used for multivariate analysis. All
P-values were two-tailed with 5% significance levels. All
statistical analyses were performed using STATA version
9.2 (Computer Resource Center, America).
Results
A total of 170 patients diagnosed with breast cancer prior
to the onset of menopause were included in this analysis,
78 were treated with a FEC regimen, 66 with a TE regi-
men, and 26 with a NE regimen. The mean age of these
patients was 42.48 y (range, 23-53 y).
Patient characteristics according to the chemotherapy
regimen received are shown in Table 1. No significant dif-
ferences were found for the three treatment groups
regarding their mean age, pathology, or use of tamoxifen.
However, an increased proportion of stage II and III can-
cers were associated with TE and NE regimens (P  <
0.001).
Univariate predictors of CIA
The rate of CIA determined for the 170 patients was
35.88%, and most amenorrhea came up after the second
or third cycle of chemotherapy. The rates of CIA accord-
ing to clinical variables are shown in Table 2. Incidence of
CIA was independently analyzed for patients 40 y and
younger versus patients older than 40 y. For these two
groups, the rates of CIA were 12.70% and 49.53%, respec-
tively (P < 0.001). It was also found that more patients 40Zhou et al. BMC Cancer 2010, 10:281
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y or younger experienced temporary amenorrhea (data
not shown) and had more regular menstruation cycles.
The impact of chemotherapy regimens on the inci-
dence of CIA was also analyzed. Rates of CIA were
44.87%, 30.30% and 23.08% for the FEC, TE and NE regi-
men groups, respectively (P = 0.068). Significant differ-
ences in the rates of CIA were not found between the
FEC and TE treatment groups (P > 0.05), but were found
between the FEC and NE treatment groups (P = 0.049).
Furthermore, no significant differences were found
between the TE and NE regimens (P  > 0.05). More
patients experienced temporary amenorrhea for TE regi-
men (data not shown). For patients receiving tamoxifen,
they were more likely to become amenorrheic (P = 0.001).
And for patients not receiving tamoxifen, more of them
had temporary amenorrhea (data not shown).
Multivariate analysis of CIA
The significant factors for CIA were age (P < 0.001), the
type of chemotherapy regimens (P = 0.009) and tamox-
ifen use (P  = 0.003) in multivariate analysis (Table 3).
When age and tamoxifen use were adjusted, the rate of
CIA for NE regimen was lower than that for FEC regimen
(P  = 0.016), but no significant differences were found
between TE and FEC regimens (P = 0.088).
Analysis of patients' preference for children
All patients were asked whether they had considered the
option to have children, or additional children, following
treatment and only 159 patients answered this question
(59 patients were ≤40 y and 100 patients were >40 y).
Twenty-nine women ≤40 y expressed a desire to have a
child compared with ten women >40 y (49.15% vs. 10.0%,
respectively) (P < 0.005) (Table 4).
Discussion
Adjuvant chemotherapy has improved the disease-free
survival and overall survival of younger patients with
breast cancer, however, the adverse effects induced by
a d j u va n t  c h e m o t h e r a p y  h a v e  n o t  bee n  w e l l  s t u d i ed .  I n
this retrospective report, we specifically evaluate CIA fol-
lowing administration of adjuvant chemotherapy and
endocrine therapy to patients diagnosed with breast can-
cer prior to the onset of menopause. When the patients
were divided into two groups based on age to evaluate
CIA, age was identified as an important predictor for
CIA. This result is consistent with previous studies where
Table 1: Patient characteristics by chemotherapy regimen received
Patient 
Characteristics
Regimen of chemotherapy P-value
FEC (n = 78) TE (n = 66) NE (n = 26)
Age at diagnosis, y
Mean 42.72 41.62 43.96 0.20
SD 5.01 6.42 6.57
Pathology
I D C 7 05 92 3 1 . 0 0
Other 8 7 3
Stage at diagnosis
I 30 (38.46%) 4 (15.38%) < 0.001
II 48 (61.54%) 36 (54.55%) 15 (57.69%)
III 30 (45.45%) 7 (26.92%)
Tamoxifen use, n (%)
Yes 55 (70.51%) 44 (66.67%) 19 (73.08%) 0.832
No 23 (29.49%) 22 (33.33%) 7 (26.92%)
SD standard deviation; IDC infitrating ductal carcinomaZhou et al. BMC Cancer 2010, 10:281
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CIA was observed to be more frequent in older women
due to a reduced number of active ovarian follicles pres-
ent [14]. In this study, rates of CIA were found to be
higher in patients older than 40 y. It has been hypothe-
sized that ovarian suppression may increase the efficacy
of chemotherapy [15], but it is not clear whether CIA
itself has an impact on prognosis or whether it is a marker
of higher bio-availability causing both ovarian destruc-
tion and tumor-cell destruction [12].
Many clinical trials have found that the addition of tax-
ane to anthracycline-based chemotherapy regimens pro-
longs the disease-free survival and overall survival of
node-positive breast cancer patients. Early in 1994, navel-
bine was reported as a first-line therapy for the treatment
of advanced breast cancer [16], and both docetaxel and
navelbine have become widely used in the treatment of
breast cancer. Previous studies showed that the incidence
of CIA in taxane-based chemotherapy regimens was
higher in anthracyclines-based chemotherapy regimens
[17-19]. In a study by Martin et al. [18], the incidence of
CIA associated with a TAC (docetaxel plus doxorubicin
and cyclophosphamide) regimen was higher than that for
a FAC (fluorouracil plus doxorubicin and cyclophosph-
amide) regimen (P = 0.007). Similarly, in a study by Han
et al. [17], a higher incidence of CIA was associated with
patients receiving taxane-containing chemotherapy (P =
0.002). In a study by Minisini et al. [20], patients receiving
taxanes have an increase risk of CIA, but these patients
recover menstrual bleeding more frequently than patients
not treated with taxanes. Despite these results, it
remained unclear whether the use of taxanes increased
the rate of CIA compared to the use of anthracyclines
alone [21]. In this study, the incidence of CIA for the FEC
regimen was higher than that for the NE regimen (P <
0.05), while no significant differences were found
between FEC and TE regimens. It has been hypothesized
that chemotherapy regimens including cyclophosph-
amide aggravate the incidence of CIA, and early studies
reported higher cyclophosphamide doses were associated
with higher rates of CIA [22,23]. In the PACS01 trial, the
incidence of CIA between 3FEC/3D and 6FEC regimens
were not found to be statistically different, although the
3FEC/3D treatment was found to induce a greater num-
ber of reversible amenorrhea cases than 6FEC [24]. Simi-
larly, in this study, more patients treated with TE regimen
experienced resumption of menstruation after temporary
amenorrhea (data not shown). An NE regimen including
epirubicin at 50 mg/m2 was previously included in the
FASG trials [25], however, the incidence of CIA associ-
ated with this NE regimen alone was not reported. In this
study, patients that received the NE regimen exhibited a
lower incidence of CIA than the other two regimens. Our
results further indicated that navelbine affected the inci-
dence of CIA less than docetaxel, but no significant dif-
ferences were found. It will be important for additional
patient cases to be analyzed to confirm the results of this
study.
Many studies have reported that administration of
tamoxifen following chemotherapy increases CIA [26,27],
Table 2: Univariate analysis of CIA
variable CIA
Age at diagnosis, y
≤40 y 8/63 (12.70%)
>40 y 53/107 (49.53%)
P-value <0.001
Chemotherapy regimen
FEC 35/78 (44.87%)
TE 20/66 (30.30%)
NE 6/26 (23.08%)
P-value 0.068
Tamoxifen use
Yes 52/117 (44.44%)
No 9/53 (16.98%)
P-value 0.001
Table 3: Multivariate analysis of CIA
Multivariate OR(95% CI) P-value of CIA
Age
(≤40 y vs. >40 y*)
0.14(0.06-0.34) <0.001
Chemotherapy
(FEC* vs. TE vs. NE)
0.51(0.30-0.84) 0.009
Tamoxifen use
(yes vs. no*)
3.69(1.54-8.83) 0.003
*Reference categoryZhou et al. BMC Cancer 2010, 10:281
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however, the IBCSG trial, 13-93, found no statistically
significant difference in the rate of CIA between patients
that received tamoxifen or not [28]. In this study, tamox-
ifen use was found to be an important predictive factor
for CIA, and the incidence of CIA was higher for patients
treated with tamoxifen than for those who did not receive
tamoxifen. These results are consistent with studies that
demonstrated tamoxifen use contributed to CIA, espe-
cially when taken over a long period of time, and tamox-
ifen has been shown to delay the resumption of menses.
Tamoxifen is additionally prescribed if patients are posi-
tive for ER and/or PR, and it results in ovaries stimulation
[29]. So tamoxifen can cause increase in follicle stimulat-
ing hormone (FSH), but also an increase in estradiol. In
fact, there was no difference in Anti Müllerian Hormone
between users and no-users of tamoxifen suggesting that
only growing follicles were influenced by tamoxifen [30].
These studies suggest that tamoxifen may be responsible
for amenorrhea but not for ovarian failure.
The diagnosis and treatment of breast cancer often
poses a threat to a patient's fertility, yet an increasing
number of young women are concerned with maintaining
their fertility in order to have children after a diagnosis of
breast cancer. For patients treated for early-stage breast
cancer, pregnancy following their treatment was not
found to adversely affect their prognosis [10]. However,
for the vast majority of women who remain amenorrheric
after 1 y of treatment, they will not regain ovarian func-
tion, resulting in loss of child-bearing potential [31].
Therefore, options to preserve fertility should be consid-
ered as early as possible if patients convey their prefer-
ence for becoming pregnant after breast cancer
treatment. Unfortunately, less than half of oncologists
discuss the possibility of treatment-related infertility with
their patients [32]. Options that are available to preserve
fertility include the use of GnRH agonists, cryopreserva-
tion of resected ovarian tissue, collection of fertilized or
non-fertilized eggs after stimulation and puncture, or
preservation of embryos that have undergone in vitro fer-
tilization. However, it is important to note that the suc-
cess of these options in maintaining women's fertility
post-treatment is uncertain [33], and currently, there are
no evidence-based recommendations for the preserva-
tion of fertility or ovarian function in breast cancer
patients [34]. However, oncologists still have a responsi-
bility to their patients to address concerns of fertility
preservation when prescribing treatment regimens for
younger breast cancer patients.
Conclusions
In conclusion, an evaluation of clinical data from 170 pre-
menopausal women diagnosed with breast cancer to
evaluate rates of CIA was performed, and the type of che-
motherapy regimen administered was found to affect the
rate of CIA. Although docetaxel and navelbine were not
associated with higher rates of CIA, cyclophosphamide
appeared to contribute to much higher rates of CIA. Fur-
thermore, patient age and tamoxifen were both found to
significantly increase rates of CIA. We suggest that the
results of this study and other clinical trials need to be
considered when patients are concerned with preserving
fertility following treatment for breast cancer.
Abbreviations
CIA: chemotherapy-induced amenorrhea; FEC: fluorouracil plus epirubicin and
cyclophosphamide; TE: docetaxel plus epirubicin; NE: navelbine plus epirubi-
cin; LHRH: luteinizing hormone releasing hormone; NCCN: National Compre-
hensive Cancer Network; G-CSF: granulocyte colony stimulating factor; ER:
estrogen receptor; PR: progesterone receptor; SD: standard deviation; IDC:
infitrating ductal carcinoma; FSH: follicle stimulating hormone
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
WBZ was responsible for analysis of data, as well as drafting the manuscript. HY
was responsible for one center (Nanjing Maternity and Child Health Care
Hospital of Nanjing Medical University). XAL, XMZ and Lin Chen were
responsible for the other center (The First Affiliated Hospital of Nanjing
Medical University). JCD performed the statistical analysis. ADT was responsi-
ble for the collection of most data. JJM was responsible for the collection of
data of patients treated in her hospital. SW was responsible for the design of
this study. Ling Chen and LJL were responsible for the collection of data and
were involved in the analysis and interpretation. All authors read and approved
the final manuscript.
Acknowledgements
The authors wish to thank Qin-hong Cao (Chinese Medicine Hospital of 
Jiangsu Province, Nanjing, China) for his expert advice on the choice of chemo-
therapy regimens. The authors thank Professor Ji-fu Wei for his help in revising 
the manuscript.
Author Details
1Department of Breast Surgery, The First Affiliated Hospital of Nanjing Medical 
University, 300 Guangzhou Road, 210029 Nanjing, PR China, 2Department of 
Breast Surgery, Nanjing Maternity and Child Health Care Hospital of Nanjing 
Medical University, Nanjing, PR China and 3Department of Epidemiology and 
Biostatistics, Nanjing Medical University School of Public Health, 140 Hanzhong 
Road, 210029 Nanjing, PR China
Received: 6 January 2010 Accepted: 11 June 2010 
Published: 11 June 2010
This article is available from: http://www.biomedcentral.com/1471-2407/10/281 © 2010 Zhou et al; licensee BioMed Central Ltd.  This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. BMC Cancer 2010, 10:281
Table 4: Patients' preferences for children post-treatment
Age at diagnosis No. of patients Desire for children P-value
≤40 y 59 29 < 0.005
>40 y 100 10Zhou et al. BMC Cancer 2010, 10:281
http://www.biomedcentral.com/1471-2407/10/281
Page 6 of 6
References
1. Jemal A, Tiwari RC, Murray T, Samuels A, Ward E, Feuer EJ, Thun MJ: Cancer 
Statistics.  CA Cancer J 2004, 54:8-29.
2. Hankey BF, Miller B, Curtis R, Kosary C: Trends in breast cancer in younger 
women in contrast to older women.  Natl Cancer Inst Monogr 1994, 
16:7-14.
3. Bines J, Oleske DM, Cobleigh MA: Ovarian function in premenopausal 
women treated with adjuvant chemotherapy for breast cancer.  J Clin 
Oncol 1996, 14:1718-1729.
4. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of 
chemotherapy and hormonal therapy for early breast cancer on 
recurrence and 15-year survival: An overview of the randomised trials.  
Lancet 2005, 365:1687-1717.
5. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thürlimann B, Senn HJ, Panel 
members: Meeting highlights: International expert consensus on the 
primary therapy of early breast cancer.  Ann Oncol 2005, 16:1569-1583.
6. Shapiro CL, Recht A: Side effects of adjuvant treatment of breast cancer.  
N Engl J Med 2001, 344:1997-2008.
7. Partridge AH, Gelber S, Peppercorn J, Sampson E, Knudsen K, Laufer M, 
Rosenberg R, Przypyszny M, Rein A, Winer EP: Web-based survey of 
fertility issue in young women with breast cancer.  J Clin Oncol 2004, 
22:4174-4222.
8. Padmanabhan N, Howell A, Rubens RD: Mechanism of action of adjuvant 
chemotherapy in early breast cancer.  Lancet 1986, 2:411-414.
9. Poikonen P, Saarto T, Elomaa I, Joensuu H, Blomqvist C: Prognostic effect 
of amenorrhea and elevated serum gonadotropin levels induced by 
adjuvant chemotherapy in premenopausal node-positive breast 
cancer patients.  Eur J Cancer 2000, 36:43-48.
10. Gelber S, Coates AS, Goldhirsch A, Castiglione-Gertsch M, Marini G, 
Lindtner J, Edelmann DZ, Gudgeon A, Harvey V, Gelber RD: Effect of 
pregnancy on overall survival after the diagnosis of early-stage breast 
cancer.  J Clin Oncol 2001, 19:1671-1675.
11. Di Cosimo S, Alimonti A, Ferretti G, Sperduti I, Carlini P, Papaldo P, Fabi A, 
Gelibter A, Ciccarese M, Giannarelli D, Mandalà M, Milella M, Ruggeri EM, 
Cognetti F: Incidence of chemotherapy-induced amenorrhea 
depending on the timing of treatment by menstrual cycle phase in 
women with early breast cancer.  Ann Oncol 2004, 15:1065-1071.
12. Rosendahl M, Ahlgren J, Andersen J, Bergh J, Blomquist C, Lidbrink E, 
Lindman H, Mouridsen H, Bjerre K, Andersson M: The risk of 
amenorrhoea after adjuvant chemotherapy for early stage breast 
cancer is related to inter-individual variations in chemotherapy-
induced leukocyte nadir in young patients: data from the randomised 
SBG 2000-1 study.  Eur J Cancer 2009, 45(18):3198-3204.
13. Fornier MN, Modi S, Panageas KS, Norton L, Hudis C: Incidence of 
chemotherapy-induced, long-term amenorrhea in patients with breast 
carcinoma age 40 years and younger after adjuvant anthracycline and 
taxane.  Cancer 2005, 104(8):1575-1579.
14. Swain SM, Land SR, Ritter MW, Costantino JP, Cecchini RS, Mamounas EP, 
Wolmark N, Ganz PA: Amenorrhea in premenopausal women on the 
doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of 
NSABP B-30 trial.  Breast Cancer Res Treat 2009, 113:315-320.
15. Walshe JM, Denduluri N, Swain SM: Amenorrhea in premenopausal 
women after adjuvant chemotherapy for breast cancer.  J Clin Oncol 
2006, 24:5769-5779.
16. Spielmann M, Dorval T, Turpin F, Antoine E, Jouve M, Maylevin F, Lacombe 
D, Rouesse J, Pouillart P, Tursz T: Phase II trial of vinorelbine/doxorubicin 
as first-line therapy of advanced breast cancer.  J Clin Oncol 1994, 
12:1764-1770.
17. Han HS, Ro J, Lee KS, Nam BH, Seo JA, Lee DH, Lee H, Lee ES, Kang HS, Kim 
SW: Analysis of chemotherapy-induced amenorrhea rates by three 
different anthracycline and taxane containing regimens for early 
breast cancer.  Breast Cancer Res Treat 2009, 115:335-342.
18. Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, 
Tomiak E, Al-Tweigeri T, Chap L, Juhos E, Guevin R, Howell A, Fornander T, 
Hainsworth J, Coleman R, Vinholes J, Modiano M, Pinter T, Tang SC, 
Colwell B, Prady C, Provencher L, Walde D, Rodriguez-Lescure A, Hugh J, 
Loret C, Rupin M, Blitz S, Jacobs P, Murawsky M, Riva A, Vogel C: Adjuvant 
docetaxel for node-positive breast cancer.  N Engl J Med 2005, 
353:2302-2313.
19. Tham YL, Sexton K, Weiss H, Elledge R, Friedman LC, Kramer R: The rates of 
chemotherapy-induced amenorrhea in patients treated with adjuvant 
doxorubicin and cyclophosphamide followed by a taxane.  Am J Clin 
Oncol 2007, 30:126-132.
20. Minisini AM, Menis J, Valent F, Andreetta C, Alessi B, Pascoletti G, Piga A, 
Fasola G, Puglisi F: Determinants of revovery from amenorrhea in 
premenopausal breast cancer patients receiving adjuvant 
chemotherapy in the taxane era.  Anticancer Drugs 2009, 20(6):503-507.
21. Pérez-Fidalgo JA, Roselló S, García-Garré E, Jordá E, Martín-Martorell P, 
Bermejo B, Chirivella I, Guzman C, Lluch A: Incidence of chemotherapy-
induced amenorrhea in hormone-sensitive breast cancer patients: the 
impact of addition of taxanes to anthracyclin-based regimens.  Breast 
Cancer Res Treat 2010, 120(1):245-251.
22. Brincker H, Rose C, Rank F, Mouridsen HT, Jakobsen A, Dombernowsky P, 
Panduro J, Andersen KW: Evidence of a castration-mediated effect of 
adjuvant cytotoxic chemotherapy inpremenopausal breast cancer.  J 
Clin Oncol 1987, 5:1771-1778.
23. Reyno LM, Levine MN, Skingley P, Arnold A, Abu Zahra H: Chemotherapy 
induced amenorrhoea in a randomised trial of adjuvant chemotherapy 
duration in breast cancer.  Eur J Cancer 1992, 29A:21-23.
24. Berliere M, Dalenc F, Malingret N, Vindevogel A, Piette P, Roche H, Donnez 
J, Symann M, Kerger J, Machiels JP: Incidence of reversible amenorrhea 
in women with breast cancer undergoing adjuvant anthracycline-
based chemotherapy with or without docetaxel.  BMC Cancer 2008, 
8:56.
25. French Adjuvant Study Group (FASG): Role of chemo-induced 
amenorrhea in premenopausal, node-positive, operable breast cancer 
patients: 9-year follow-up results of French Adjuvant Study Group data 
base.  Breast Cancer Res Treat 2003, 82:S30. (abs138)
26. Boccardo F, Rubagotti A, Bruzzi P, Cappellini M, Isola G, Nenci I, Piffanelli A, 
Scanni A, Sismondi P, Santi L: Chemotherapy versus tamoxifen versus 
chemotherapy plus tamoxifen in node-positive, estrogen receptor-
positive brease cancer patients: results of a multicentric Italian study.  J 
Clin Oncol 1990, 8:1310-1320.
27. Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N: Risk of menopause 
during the first year after breast cancer diagnosis.  J Clin Oncol 1999, 
17:2365-2370.
28. International Breast Cancer Study Group: Tamoxifen after adjuvant 
chemotherapy for premenopausal women with lymphnode positive 
breast cancer: international breast cancer study group trial 13-93.  J 
Clin Oncol 2006, 24:1332-1341.
29. Oktay K, Buyuk E, Libertella N, Akar M, Rosenwaks Z: Fertility preservation 
in breast cancer patients: a prospective controlled comparison of 
ovarian stimulation with tamoxifen and letrozole for embryo 
cryopreservation.  J Clin Oncol 2005, 23(19):4347-4353.
30. Rosendahl M, Andersen CY, Ernst E, Westergaard LG, Rasmussen PE, Loft A, 
Andersen AN: Ovarian function after removal of an entire ovary for 
cryopreservation of pieces of cortex prior to gonadotoxic treatment: a 
follow-up study.  Hum Reprod 2008, 23(11):2475-2483.
31. Partridge AH, Burstein HJ, Winer EP: Side effects of chemotherapy and 
combined chemohormonal therapy in women with early-stage breast 
cancer.  J Natl Cancer Inst Monogr 2001, 30:135-142.
32. Lee SJ, Schover LR, Partridge AH, Patrizio P, Wallace WH, Hagerty K, Beck 
LN, Brennan LV, Oktay K: American society of clinical oncology 
recommendations on fertility preservation in cancer patients.  J Clin 
Oncol 2006, 24:2917-2931.
33. Petrek JA, Naughton MJ, Case LD, Paskett ED, Naftalis EZ, Singletary SE, 
Sukumvanich P: Incidence, time course, and determinants of menstrual 
bleeding after breast cancer treatment: a prospective study.  J Clin 
Oncol 2006, 24:1045-1051.
34. Gerber B, Dieterich M, Müller H, Reimer T: Controversies in preservation 
of ovary function and fertility in patients with breast cancer.  Breast 
Cancer Res Treat 2008, 108:1-7.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2407/10/281/prepub
doi: 10.1186/1471-2407-10-281
Cite this article as: Zhou et al., Incidence of chemotherapy-induced amen-
orrhea associated with epirubicin, docetaxel and navelbine in younger breast 
cancer patients BMC Cancer 2010, 10:281